The development of resistance to conventional treatment has led WHO to recommend the use of combination therapies containing artemisinin derivative (artemisinin-based combination therapies also known as ACTs). All of the following combination therapies are recommended if such resistance is suspected, except
The WHO recommended ACTs include:

Artemether-lumefantrine
Artesunate-amodiaquine
Artesunate-mefloquine
Artesunate-sulfadoxine-pyrimethamine
Dihydroartemisinin-piperaquine
Artemether plus lumefantrine
Artesunate plus quinine
Artesunate plus pyrimethamine-sulfadoxine
Artesunate plus mefloquine